Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen, Cytokinetics Checked With Payers Before Taking Omecamtiv Into Phase III

02 Sep 2016

• By Joseph Haas

molecule

Related Content

Novartis' <em>Entresto</em>: Slow Uptake Expected Following Fast FDA Approval

13 Jul 2015

Amgen, Cytokinetics' heart drug misses goal in Phase II study

03 Sep 2013

Cytokinetics Seeks ALS Success By Focusing On Lung Function

19 Aug 2016

Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No

19 Jul 2016

Cytokinetics Awaits Amgen's Phase III Plan After Phase II Heart Drug Success

11 Nov 2015

Related Companies

Amgen, Inc.

Cytokinetics, Inc.

Novartis AG

Les Laboratoires Servier

Astellas Pharma, Inc.

Additional Topics

Clinical Trials Reimbursement Commercial Cardiovascular BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.